Macrogol Toho

Macrogol

Method of action: Laxative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Macrogol Toho

Property	Description
Active Ingredient	Macrogol (Polyethylene Glycol)
Form	Powder for oral solution, Oral solution
Pharmacological Class	Osmotic laxative
General Purpose	To promote comfortable bowel evacuation
Origin	Synthetic polymer

What Type of Medicine is Macrogol Toho?

Macrogol Toho is a pharmaceutical preparation containing the active ingredient Macrogol, which is the International Nonproprietary Name (INN) for Polyethylene Glycol (PEG). It is formally classified as an osmotic laxative, a type of medicine designed to work primarily within the gastrointestinal tract to assist in the gentle and natural evacuation of intestinal contents. The inclusion of Macrogol in the preparation places it within the osmotic laxative pharmacological class.

Formulations based on this INN, such as Movicol or Miralax, are clinically recognized for their effectiveness in addressing symptoms where enhanced stool hydration is beneficial. The Macrogol compound is inert, designed to be highly hydrophilic, which restricts its beneficial effect entirely to the gut after oral administration.

Composition, Origin, and Forms of Macrogol

The therapeutic effectiveness of the preparation is derived from Macrogol, which is defined as a synthetic, high-molecular-weight polymer that is metabolically inert within the human digestive system. Macrogol Toho is typically supplied as a powder for oral solution requiring mixing with an aqueous liquid base before consumption. The high molecular weight (e.g., Macrogol 3350) is critical to its function, ensuring negligible intestinal absorption into the bloodstream.

While some preparations contain Macrogol as a single ingredient, many common formulations are a combination product that includes essential electrolytes (such as sodium and potassium salts). These electrolytes are added to help maintain the body's natural mineral balance, which is particularly relevant when treating conditions in elderly subjects or paediatric patient groups where fluid balance is a significant consideration.

How Does Macrogol Toho Generally Function?

Macrogol Toho generally functions by employing a localized osmotic effect within the bowel, which is its fundamental mechanism principle. The Macrogol compound travels through the gastrointestinal tract virtually unchanged and acts as a solute that effectively attracts and holds water molecules within the intestinal contents as it passes through the colon.

This essential action of water retention directly softens the stool consistency and increases its volume, or bulk. The resulting general benefit of this preparation is the promotion of easier, more comfortable bowel movements by physically conditioning the intestinal contents, thereby alleviating difficulty associated with hard, dry stool without stimulating intestinal nerves.

Regulatory References

National Institutes of Health (NIH)

What side effects are possible with Macrogol Toho?

Macrogol-based products, which include formulations with electrolytes, have an officially documented safety profile characterized primarily by Gastrointestinal Disorders and the identification of rare, but serious, post-marketing events.

Adverse Reactions Summary

Adverse reactions most commonly involve the gastrointestinal tract, often as a result of the product's function in increasing gut motility and content expansion. These effects are generally classified as Common and include abdominal pain, distension, nausea, vomiting, flatulence, and diarrhea. Mild diarrhea often resolves with a dose reduction. Rare but significant allergic reactions are also documented, encompassing anaphylactic shock, angioedema, urticaria, rash, and pruritus.

System Organ Class	Common Reactions (Example)	Serious Reactions (Frequency Not Known)
Gastrointestinal Disorders	Abdominal pain, Nausea, Diarrhea	Oesophageal rupture (Boerhaave syndrome)*
Nervous System Disorders	Headache	Seizure
Immune System Disorders	Allergic skin reactions	Anaphylactic reactions

*Oesophageal rupture has been reported post-marketing, mostly in elderly patients, associated with excessive vomiting after intake for bowel preparation. Seizures have been reported, primarily linked to electrolyte abnormalities, such as severe hyponatraemia.

Safety Considerations and Restrictions

Contraindications strictly prohibit the use of Macrogol Toho in individuals with intestinal perforation or obstruction, ileus, or severe inflammatory bowel diseases, including active Crohn's disease, ulcerative colitis, and toxic megacolon.

Caution is advised in patients with a history of seizures, those at risk of electrolyte imbalance (such as patients with heart failure, renal impairment, or on diuretics), and the elderly. If neurological symptoms occur, a check and correction of fluid and electrolyte levels are advised by regulatory bodies. Patients should be informed about the immediate need for medical assistance if they experience incoercible vomiting accompanied by severe chest or abdominal pain, as this may indicate a serious complication.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents state that an overdosage of Macrogol (Polyethylene Glycol) is primarily characterized by severe diarrhea, which is the major expected clinical event resulting from the medicine’s excessive osmotic action in the intestine. Because the active ingredient is negligibly absorbed into the bloodstream, the documented adverse outcomes are primarily related to fluid balance rather than systemic toxicity.

Overdose Manifestation	Potential Severe Outcome	Management Action
Diarrhea (Major expected event)	Dehydration (If fluid is not administered)	Terminate medication
Abdominal Distention	Electrolyte Imbalance	Administer free water

A serious outcome is the risk of dehydration and subsequent electrolyte imbalance, particularly when overdosage occurs without the adequate replacement of fluid lost through diarrhea. Overdosage without sufficient concomitant fluid ingestion is specifically noted as accelerating this risk. Certain patient populations, such as elderly nursing home patients, are listed as having a higher susceptibility to high-dose dose-related effects. Management is supportive and symptomatic, as no specific antidote is known for Macrogol overdosage.

Emergency Actions

Regulators mandate that in the event of suspected overdosage, the user must get medical help or contact a Poison Control Center right away. All patients require immediate professional assistance to address potential fluid volume deficits and ensure electrolyte status is managed. This action is critical for minimizing the progression of severe fluid loss.

Therapeutic Uses of Macrogol Toho

What Macrogol Toho Treats: Main Uses and Benefits

Macrogol (Polyethylene Glycol or PEG) is widely used. Its primary purpose is to address symptoms related to physical discomfort and strain caused by constipation. It is relevant for easing symptoms in cases of both chronic constipation and for the treatment of faecal impaction, a condition associated with a severe build-up of hardened stool.

Macrogol is used for the management of constipation. It is considered relevant for easing symptoms in situations where patients experience these symptoms. It is commonly used across conditions presenting with acute episodes or conditions involving episodic or fluctuating manifestations of difficulty with bowel movements. As an osmotic agent, macrogol plays a role in managing symptoms by hydrating the stool. This action assists with maintaining functional stability and contributes to easing the overall symptom load.

The supportive relief provided by macrogol may assist with maintaining a sense of stability when symptoms are more noticeable. It supports the patient by providing relief when symptoms interfere with routine activities.

“It is considered relevant in contexts involving heightened systemic burden and may be part of supportive symptom management.”

Quick Fact: Relief for Symptoms related to physical discomfort

Regulatory References

NIH StatPearls - National Library of Medicine

Eligibility and Restrictions for Use

Who Can and Cannot Use Macrogol

Eligibility for Macrogol (Polyethylene Glycol) is strictly defined by official regulatory criteria, primarily concerning contraindications and patient status. The medicine is absolutely prohibited for patients with:

Known hypersensitivity to Macrogol or any excipient (e.g., Aspartame in Phenylketonuria).
Intestinal obstruction (ileus), intestinal perforation or a high risk of perforation, or toxic megacolon.
Severe inflammatory bowel diseases, such as active Crohn's Disease or Ulcerative Colitis.

Age and Special Populations

Standard adult formulations are generally not recommended for children under 12 years of age; pediatric use requires specific, lower-strength formulations approved for children, typically starting from age two. Older adults are eligible but require special caution due to an elevated risk of fluid and electrolyte imbalances.

Conditional Use

Use is allowed with special precaution and monitoring for patients with pre-existing severe electrolyte disturbances, severely impaired renal function, or significant cardiovascular impairment. Regulatory data indicates Macrogol can be used during pregnancy and breastfeeding as systemic absorption is negligible, minimizing anticipated effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Macrogol Toho may interact with other orally administered medicinal products. Official regulatory documentation indicates that the drug is not absorbed systemically, and its primary interaction mechanism is local, reducing the absorption and potentially the efficacy of co-administered oral medicines.

This pharmacokinetic interaction results from the increased fluid volume and accelerated transit time in the gastrointestinal tract. This effect is considered particularly clinically significant for drugs that have a narrow therapeutic index or a short half-life, where even a small reduction in absorption can lead to therapeutic failure.

Documented Interaction Constraints

The following interaction constraints and potentially affected drug classes are specifically addressed in official labeling:

Constraint / Condition	Practical Implication
Timing-based separation rule	Do not take Macrogol Toho within two hours of taking any other oral medication.
Narrow Therapeutic Index Agents	Use with caution or avoid combination with drugs like digoxin, antiepileptics (e.g., phenytoin), coumarins, and immunosuppressants.

This required spacing is the procedural constraint designed to mitigate the risk of reduced drug absorption. The interaction profile is solely defined by this transient, non-systemic effect on the absorption of other oral agents.

Mechanism of Action

Macrogol (polyethylene glycol) functions as a biologically inert polymer that achieves its systemic effect solely through physical and osmotic action within the gastrointestinal lumen. It is not absorbed systemically and does not engage biological targets such as receptors, enzymes, or ion channels.

Osmotic Fluid Regulation

Macrogol acts as a localized osmotic agent in the colon. Its molecules strongly bind to water via hydrogen bonds, preventing the subsequent passive reabsorption of fluid from the bowel into the systemic circulation. This non-systemic interaction promotes the retention of fluid and the Macrogol structure within the gut lumen, functioning as a primary physical modification pathway.

Luminal Volume and Stool Rheology

This fluid retention increases the overall luminal volume and the total water content of the stool mass. The resulting increase in mass volume and water content alters the stool’s physicochemical properties, specifically contributing to a reduction in fecal viscosity.

Mechanical Bowel Motility

This physical expansion of the stool mass results in distension of the colon wall. This mechanical distension stimulates the intrinsic signaling sequences for peristalsis, the natural, wave-like muscular contractions of the colon, leading to enhanced peristaltic activity and subsequent propulsion of the contents through the bowel.

Dosage and Administration Information

How to Use Macrogol Toho: Official Administration Guidelines

Macrogol Toho, a Macrogol (Polyethylene Glycol) preparation, is administered solely via the oral route as a solution. The instructions below outline the standardized use protocols for this medicine.

Administration and Preparation

The medicine is supplied as a powder for oral solution. It can be taken at any time of day, independent of meals or drinks. For proper use, the powder must be reconstituted:

Dilution: Each prescribed sachet must be dissolved in approximately 125 mL of water or other suitable liquid before consumption.
Fluid Intake: Patients are advised to maintain adequate regular fluid intake in addition to the fluid used for the medicine's preparation.

Standard Dosing and Duration (ge 12 Years)

The official dosing regimens for adults and adolescents are strictly conditional on the use case:

Condition	Standard Regimen	Treatment Duration	Special Constraints
Chronic Constipation	Start with 1 sachet daily; adjust up to 3 sachets daily.	Treatment should not normally exceed 2 weeks.	Doses are stable for patients with renal impairment (kidney issues).
Faecal Impaction	A total of 8 sachets daily.	Treatment should not normally exceed 3 days.	The 8 sachets must be consumed within a 6 hour period; patients with cardiovascular impairment must not take more than two sachets per hour.

For chronic conditions requiring long-term treatment, the dose may be reduced to 1 or 2 sachets daily, only under medical supervision.

Procedural Summary

These official guidelines establish the precise reconstitution and oral administration protocol, define the fixed and time-limited dosing for both chronic constipation and faecal impaction, and incorporate mandatory rate restrictions for administration in specific populations.

Recent Clinical Evidence

Macrogol Toho: Recent Clinical Evidence

Evidence for Use in Chronic Constipation

Macrogol was studied for chronic functional constipation, and research is extensive, primarily relying on Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews and Meta-analyses. Studies monitored functional metrics like weekly bowel movement frequency and stool consistency, along with patient-reported outcomes describing perceived discomfort. While research is extensive, long-term effects regarding continuous or intermittent routine use are not fully established, as most RCTs have focused on follow-up durations of six months or less.

Evidence for Use in Acute Scenarios

Macrogol was studied for the acute treatment of faecal impaction, a condition associated with a severe build-up of hardened stool. Research for this acute condition consists of Short-term RCTs, and evidence supports the study of Macrogol for this purpose, often being cited in relevant clinical literature. The primary metric measured in these acute trials was the successful resolution of the impaction over short treatment periods.

Evidence in Specific Subgroups

Macrogol was studied for adults who have constipation associated with Irritable Bowel Syndrome (IBS-C). Trials examined outcomes related to bowel function and abdominal pain severity scores. Research describes measurements of functional constipation metrics, but findings were mixed, and certainty remains low regarding the consistent relief of associated abdominal discomfort compared to functional improvements.

Research Gaps and Limitations

The research base highlights limitations across several areas. Follow-up durations were limited in most trials, and there is insufficient information for long-term outcomes on functional patterns. Furthermore, data for specific populations like pregnant women or patients with complex underlying comorbidities remain insufficient. For groups that have been studied, such as children and older adults, the results apply only to the populations observed in those specific trials, and comparative evidence against certain other laxative formulations is lacking.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Macrogol Toho (FAQ)

Q: What is the main use of Macrogol Toho?

Macrogol Toho is officially indicated for the treatment of chronic constipation in both adults and children who are 2 years of age and older. It functions as an osmotic laxative, which helps to soften stool and increase bowel movement frequency. The official product information specifies this primary indication across all approved age groups.

Q: How long does it take for Macrogol Toho to start working?

Clinical studies and official information suggest that this medication typically begins to produce effects within 1 to 2 days of starting treatment. The exact time it takes to see a result can vary among individuals. Its regulatory classification means it is not characterized as an instant-acting treatment.

Q: Is Macrogol Toho addictive?

According to the official product information and safety data, there is no evidence of addiction or tolerance development associated with Macrogol Toho. Regulatory documents state that the medication does not show abuse potential in clinical studies up to the tested duration. This means that users are not expected to become physically dependent on the medication.

Q: Can I take this medication with food?

Regulatory documents indicate that Macrogol Toho can be taken at any time of the day, regardless of meals. It can be mixed and consumed either with or without food. This administration guidance provides flexibility for patients incorporating the medication into their daily schedule.

Q: Does Macrogol Toho treat stomach pain?

Macrogol Toho is officially indicated for treating chronic constipation. While resolving constipation may offer relief from associated symptoms like stomach discomfort or cramping, it is not approved as a primary pain reliever. Official guidelines recommend seeking medical advice for persistent or severe symptoms.

Q: Is it safe for children under 2?

Official product documentation states that Macrogol Toho is not indicated or studied in children younger than 2 years of age. Consequently, there is insufficient regulatory data to support its use or safety profile for this age group. The management of constipation in children under 2 years of age typically requires clinical supervision.

Q: Do I need a prescription to get Macrogol Toho?

Availability and the necessity of a prescription can vary significantly by country or region. While the product holds an over-the-counter classification in many areas, specific national regulations determine how it is scheduled and sold. Patients should review the current regulatory status in their local area.

Q: How long is it safe to use Macrogol Toho continuously?

Regulatory guidelines acknowledge that short-term use of Macrogol Toho is common and well-supported by data. If the condition requiring use continues for an extended period, such as longer than two weeks, patients are generally advised to consult with a healthcare professional. This action is recommended to ensure appropriate oversight and management.

Q: Can Macrogol Toho be mixed with juice instead of water?

The patient information leaflet indicates that the powder can generally be mixed with various cold beverages beyond just water. This includes juice or other cold drinks, provided the full dose is dissolved correctly. Official administration guidance recommends prompt consumption after mixing to ensure the full dose is effective.

How should Macrogol Toho be stored and disposed of?

Storage and Disposal Requirements for Macrogol (Polyethylene Glycol)

The official guidelines for Macrogol powder ensure product stability and safety, encompassing specific temperature, protection, and disposal rules.

Official Storage Conditions

Item	Requirement
Powder Temperature	Store at or below 25°C (77°F).
Protection	Keep in the original container to protect from light and moisture; keep out of the sight and reach of children.
Prepared Solution	Store in the refrigerator (2°C to 8°C); discard after 24 hours.

Official Disposal Instructions

Unused or expired Macrogol must not be thrown away with household trash or via wastewater. For proper disposal, individuals must consult a pharmacist to ensure compliance with local pharmaceutical waste regulations and to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Japan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z